Download PDF
Nervenheilkunde 2021; 40(03): 154-159
DOI: 10.1055/a-1246-0358
Schwerpunkt

Entwicklung sekundärer Kopfschmerzen durch Exposition oder Übergebrauch einer Substanz

Secondary headache attributed to exposure or overuse of a substance
Britta Lenz∗
1   Klinik für Neurologie, Evangelisches Krankenhaus Unna
2   Abteilung für Neurologie, Bundeswehrzentralkrankenhaus Koblenz
,
Mark Obermann∗
3   Zentrum für Neurologie, Asklepios-Krankenhäuser Schildautal, Seesen
4   Klinik für Neurologie, Universität Duisburg-Essen, Essen
,
Zaza Katsarava∗
1   Klinik für Neurologie, Evangelisches Krankenhaus Unna
4   Klinik für Neurologie, Universität Duisburg-Essen, Essen
5   EVEX Medizinische Gesellschaft EVEX, Tiflis, Republik Georgien
6   IM Sechenow Erste Staatliche Medizinische Universität Moskau (Sechenow-Universität), Moskau, Russland
› Author Affiliations
› Further Information
    Permissions and Reprints

ZUSAMMENFASSUNG

Sekundäre Kopfschmerzen, die auf die Exposition, den Übergebrauch oder den Entzug einer Substanz zurückzuführen sind, sind in Kapitel 8 der 3. Auflage der Internationalen Klassifikation von Kopfschmerzerkrankungen (ICHD-3) aufgeführt. Es werden 3 Unterkapitel unterschieden: 8.1. Kopfschmerz zurückzuführen auf Substanzgebrauch oder Substanzexposition, 8.2. Kopfschmerz zurückzuführen auf einen Medikamentenübergebrauch und 8.3. Kopfschmerz zurückzuführen auf den Entzug einer Substanz. Ersterer – Kopfschmerz zurückzuführen auf Substanzgebrauch oder Substanzexposition – bezieht sich auf einen Kopfschmerz mit Beginn unmittelbar oder innerhalb von Stunden nach der Exposition. Hingegen ist der „Kopfschmerz zurückzuführen auf einen Medikamentenübergebrauch“ (MOH) definiert als ein Kopfschmerz, der an 15 oder mehr Tagen pro Monat bei Patienten mit einer vorbestehenden primären Kopfschmerzerkrankung auftritt und sich als Folge der regelmäßigen Einnahme akuter Kopfschmerzmedikamenten über einen Zeitraum von mehr als 3 aufeinanderfolgende Monate entwickelt hat. Bezüglich letzterem, ist der Entzug von Koffein, Östrogen und Opioiden am häufigsten mit der Entwicklung von Kopfschmerzen assoziiert.

Der vorliegende Artikel soll einen Überblick über die neuesten Erkenntnisse zur Klassifikation, Pathophysiologie und zu Behandlungsstrategien dieser sekundären Kopfschmerzentitäten geben und legt den Schwerpunkt dabei auf die Unterkapitel 8.1 und 8.2. der ICHD-3-Klassifikation.

ABSTRACT

Secondary headaches attributed to exposure, overuse or withdrawal of a substance are listed in chapter eight of the 3 rd edition of the International Classification of Headache Disorders (ICHD-3). Three sub-chapters are distinguished: 8.1 Headache attributed to use of or exposure to a substance, 8.2 Medication-overuse headache (MOH) and 8.3 Headache attributed to substance withdrawal. Headache attributed to substance use or substance exposure refers to a headache that begins immediately or within hours after exposure. Medication-overuse headache (MOH) is defined as a headache that occurs on 15 or more days per month in patients with a pre-existing primary headache disorder and develops as a result of regular use of acute headache medication for more than three consecutive months. Regarding the latter, withdrawal of caffeine, estrogen and opioids is most commonly associated with the development of headache.

This article aims to provide an overview of the latest knowledge on the classification, pathophysiology and treatment strategies for these secondary headache disorders, focusing on subchapters 8.1 and 8.2 of the ICHD-3 classification.

Schlüsselwörter

Kopfschmerz bei Medikamentenübergebrauch - sekundärer Kopfschmerz - Substanz - Exposition - Entzug

Key words

Medication-overuse headache - secondary headache - substance - exposure - withdrawal


Publication History

Article published online:
09 March 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3 rd edition. Cephalalgia. 2018; 38 (01) 1-211
    PubMedGoogle Scholar
  • 2 Iversen HK, Olesen J, Tfelt-Hansen P. Intravenous nitroglycerin as an experimental model of vascular headache. Basic characteristics. Pain 1989; 38 (01) 17-24
    CrossrefPubMedGoogle Scholar
  • 3 Lipton RB, Choy-Kwong M, Solomon S. Headaches in hospitalized cocaine users. Headache 1989; 29 (04) 225-8
    CrossrefPubMedGoogle Scholar
  • 4 Kruuse C, Thomsen LL, Jacobsen TB. et al The phosphodiesterase 5 inhibitor sildenafil has no effect on cerebral blood flow or blood velocity, but nevertheless induces headache in healthy subjects. J Cereb Blood Flow Metab 2002; 22 (09) 1124-31
    CrossrefPubMedGoogle Scholar
  • 5 Ashina M, Bendtsen L, Jensen R. et al Nitric oxide-induced headache in patients with chronic tension-type headache. Brain 2000; 123 Pt 9 1830-7
    CrossrefPubMedGoogle Scholar
  • 6 Kruuse C, Thomsen LL, Birk S. et al Migraine can be induced by sildenafil without changes in middle cerebral artery diameter. Brain 2003; 126 Pt 1 241-7
    CrossrefPubMedGoogle Scholar
  • 7 Ashina M, Hansen JM, ÁDunga BO. et al Human models of migraine – short-term pain for long-term gain. Nat Rev Neurol. 2017; 13 (12) 713-24
    CrossrefPubMedGoogle Scholar
  • 8 Olesen J, Ashina M. Can nitric oxide induce migraine in normal individuals?. Cephalalgia 2015; 35 (12) 1125-9
    CrossrefPubMedGoogle Scholar
  • 9 Gozalov A, Jansen-Olesen I, Klaerke D. et al Role of BK(Ca) channels in cephalic vasodilation induced by CGRP, NO and transcranial electrical stimulation in the rat. Cephalalgia 2007; 27 (10) 1120-7
    CrossrefPubMedGoogle Scholar
  • 10 Strecker T, Dux M, Messlinger K. Nitric oxide releases calcitonin-gene-related peptide from rat dura mater encephali promoting increases in meningeal blood flow. J Vasc Res 2002; 39 (06) 489-96
    CrossrefPubMedGoogle Scholar
  • 11 Olesen J, Thomsen LL, Iversen H. Nitric oxide is a key molecule in migraine and other vascular headaches. Trends Pharmacol Sci 1994; 15 (05) 149-53
    CrossrefPubMedGoogle Scholar
  • 12 De Col R, Koulchitsky SV, Messlinger KB. Nitric oxide synthase inhibition lowers activity of neurons with meningeal input in the rat spinal trigeminal nucleus. Neuroreport 2003; 14 (02) 229-32
    CrossrefPubMedGoogle Scholar
  • 13 Tfelt-Hansen P, Daugaard D, Lassen LH, Iet al. Prednisolone reduces nitric oxide-induced migraine. Eur J Neurol 2009; 16 (10) 1106-11
    CrossrefPubMedGoogle Scholar
  • 14 Thomaides T, Karapanayiotides T, Kerezoudi E. et al Intravenous valproate aborts glyceryl trinitrate-induced migraine attacks: a clinical and quantitative EEG study. Cephalalgia 2008; 28 (03) 250-6
    CrossrefPubMedGoogle Scholar
  • 15 Luthringer R, Djupesland PG, Sheldrake CD. et al Rapid absorption of sumatriptan powder and effects on glyceryl trinitrate model of headache following intranasal delivery using a novel bi-directional device. J Pharm Pharmacol 2009; 61 (09) 1219-28
    CrossrefPubMedGoogle Scholar
  • 16 Ashina M, Lassen LH, Bendtsen L. et al Effect of inhibition of nitric oxide synthase on chronic tension-type headache: a randomised crossover trial. Lancet 1999; 353 9149 287-9
    CrossrefPubMedGoogle Scholar
  • 17 Lassen LH, Christiansen I, Iversen HK. et al The effect of nitric oxide synthase inhibition on histamine induced headache and arterial dilatation in migraineurs. Cephalalgia. 2003; 23 (09) 877-86
    CrossrefPubMedGoogle Scholar
  • 18 Diener HC, Holle D, Solbach K. et al Medication-overuse headache: risk factors, pathophysiology and management. Nat Rev Neurol 2016; 12 (10) 575-83
    CrossrefPubMedGoogle Scholar
  • 19 Castillo J, Muñoz P, Guitera V. et al Kaplan Award 1998. Epidemiology of chronic daily headache in the general population. Headache 1999; 39 (03) 190-6
    CrossrefPubMedGoogle Scholar
  • 20 Prencipe M, Casini AR, Ferretti C. et al Prevalence of headache in an elderly population: attack frequency, disability, and use of medication. J Neurol Neurosurg Psychiatry. 2001; 70 (03) 377-81
    CrossrefPubMedGoogle Scholar
  • 21 Lantéri-Minet M, Auray JP, El Hasnaoui A. et al Prevalence and description of chronic daily headache in the general population in France. Pain 2003; 102 1–2 143-9
    CrossrefPubMedGoogle Scholar
  • 22 Straube A, Pfaffenrath V, Ladwig KH. et al Prevalence of chronic migraine and medication overuse headache in Germany-the German DMKG headache study. Cephalalgia 2010; 30 (02) 207-13
    CrossrefPubMedGoogle Scholar
  • 23 Hagen K, Vatten L, Stovner LJ. et al Low socio-economic status is associated with increased risk of frequent headache: a prospective study of 22718 adults in Norway. Cephalalgia 2002; 22 (08) 672-9
    CrossrefPubMedGoogle Scholar
  • 24 Westergaard ML, Glümer C, Hansen EH. et al Prevalence of chronic headache with and without medication overuse: associations with socioeconomic position and physical and mental health status. Pain 2014; 155 (10) 2005-13
    CrossrefPubMedGoogle Scholar
  • 25 Katsarava Z, Dzagnidze A, Kukava M. et al Primary headache disorders in the Republic of Georgia: prevalence and risk factors. Neurology 2009; 73 (21) 1796-803
    CrossrefPubMedGoogle Scholar
  • 26 Ayzenberg I, Katsarava Z, Sborowski A. et al The prevalence of primary headache disorders in Russia: a countrywide survey. Cephalalgia 2012; 32 (05) 373-81
    CrossrefPubMedGoogle Scholar
  • 27 Bigal ME, Serrano D, Buse D. et al Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache 2008; 48 (08) 1157-68
    CrossrefPubMedGoogle Scholar
  • 28 Paemeleire K, Bahra A, Evers S. et al Medication-overuse headache in patients with cluster headache. Neurology 2006; 67 (01) 109-13
    CrossrefPubMedGoogle Scholar
  • 29 Thorlund K, Sun-Edelstein C, Druyts E. et al Risk of medication overuse headache across classes of treatments for acute migraine. J Headache Pain 2016; 17 (01) 107
    CrossrefPubMedGoogle Scholar
  • 30 Hagen K, Albretsen C, Vilming ST. et al A 4-year follow-up of patients with medication-overuse headache previously included in a randomized multicentre study. J Headache Pain 2011; 12 (03) 315-22
    CrossrefPubMedGoogle Scholar
  • 31 Ashina S, Serrano D, Lipton RB. et al Depression and risk of transformation of episodic to chronic migraine. J Headache Pain 2012; 13 (08) 615-24
    CrossrefPubMedGoogle Scholar
  • 32 Cevoli S, Sancisi E, Grimaldi D. et al Family history for chronic headache and drug overuse as a risk factor for headache chronification. Headache 2009; 49 (03) 412-8
    CrossrefPubMedGoogle Scholar
  • 33 Kristoffersen ES, Straand J, Russell MB. et al Disability, anxiety and depression in patients with medication-overuse headache in primary care – the BIMOH study. Eur J Neurol 2016; 23 (01) 28-35
    CrossrefPubMedGoogle Scholar
  • 34 Lampl C, Thomas H, Tassorelli C. et al Headache, depression and anxiety: associations in the Eurolight project. J Headache Pain 2016; 17: 59
    CrossrefPubMedGoogle Scholar
  • 35 Cupini LM, De Murtas M, Costa C. et al Obsessive-compulsive disorder and migraine with medication-overuse headache. Headache 2009; 49 (07) 1005-13
    CrossrefPubMedGoogle Scholar
  • 36 Scher AI, Stewart WF, Ricci JA. et al Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain 2003; 106 1–2 81-9
    CrossrefPubMedGoogle Scholar
  • 37 Sancisi E, Cevoli S, Vignatelli L. et al Increased prevalence of sleep disorders in chronic headache: a case-control study. Headache 2010; 50 (09) 1464-72
    CrossrefPubMedGoogle Scholar
  • 38 Cargnin S, Viana M, Sances G. et al A systematic review and critical appraisal of gene polymorphism association studies in medication-overuse headache. Cephalalgia 2018; 38 (07) 1361-73
    CrossrefPubMedGoogle Scholar
  • 39 Potewiratnanond P, le Grand SM, Srikiatkhachorn A. et al Altered activity in the nucleus raphe magnus underlies cortical hyperexcitability and facilitates trigeminal nociception in a rat model of medication overuse headache. BMC Neurosci 2019; 20 (01) 54
    CrossrefPubMedGoogle Scholar
  • 40 Srikiatkhachorn A, le Grand SM, Supornsilpchai W. et al Pathophysiology of medication overuse headache-an update. Headache 2014; 54 (01) 204-10
    CrossrefPubMedGoogle Scholar
  • 41 De Felice M, Ossipov MH, Wang R. et al Triptan-induced latent sensitization: a possible basis for medication overuse headache. Ann Neurol 2010; 67 (03) 325-37
    CrossrefPubMedGoogle Scholar
  • 42 Green AL, Gu P, De Felice M. et al Increased susceptibility to cortical spreading depression in an animal model of medication-overuse headache. Cephalalgia 2014; 34 (08) 594-604
    CrossrefPubMedGoogle Scholar
  • 43 Ayzenberg I, Obermann M, Nyhuis P. et al Central sensitization of the trigeminal and somatic nociceptive systems in medication overuse headache mainly involves cerebral supraspinal structures. Cephalalgia 2006; 26 (09) 1106-14
    CrossrefPubMedGoogle Scholar
  • 44 Lai TH, Wang SJ. Neuroimaging Findings in Patients with Medication Overuse Headache. Curr Pain Headache Rep 2018; 22 (01) 1
    CrossrefPubMedGoogle Scholar
  • 45 Schwedt TJ, Chong CD. Medication Overuse Headache: Pathophysiological Insights from Structural and Functional Brain MRI Research. Headache 2017; 57 (07) 1173-8
    CrossrefPubMedGoogle Scholar
  • 46 Carlsen LN, Westergaard ML, Bisgaard M. et al National awareness campaign to prevent medication-overuse headache in Denmark. Cephalalgia 2018; 38 (07) 1316-25
    CrossrefPubMedGoogle Scholar
  • 47 Grande RB, Aaseth K, Benth J, Let al. Reduction in medication-overuse headache after short information. The Akershus study of chronic headache. Eur J Neurol 2011; 18 (01) 1 29-37
    CrossrefPubMedGoogle Scholar
  • 48 Rossi P, Faroni JV, Tassorelli C. et al Advice alone versus structured detoxification programmes for complicated medication overuse headache (MOH): a prospective, randomized, open-label trial. J Headache Pain 2013; 14: 10
    CrossrefPubMedGoogle Scholar
  • 49 Kristoffersen ES, Straand J, Vetvik KGB. et al Brief intervention for medication-overuse headache in primary care. The BIMOH study: a double-blind pragmatic cluster randomised parallel controlled trial. J Neurol Neurosurg Psychiatry 2015; 86 (05) 505-12
    CrossrefPubMedGoogle Scholar
  • 50 Katsarava Z, Fritsche G, Muessig M. et al Clinical features of withdrawal headache following overuse of triptans and other headache drugs. Neurology 2001; 57 (09) 1694-8
    CrossrefPubMedGoogle Scholar
  • 51 Evers S, Jensen R, Societies EFoN. Treatment of medication overuse headache-guideline of the EFNS headache panel. Eur J Neurol 2011; 18 (09) 1115-21
    CrossrefPubMedGoogle Scholar
  • 52 Diener HC, Dodick D, Evers S. et al Pathophysiology, prevention, and treatment of medication overuse headache. Lancet Neurol 2019; 18 (09) 891-902
    CrossrefPubMedGoogle Scholar
  • 53 Engelstoft IMS, Carlsen LN, Munksgaard SB. et al Complete withdrawal is the most feasible treatment for medication-overuse headache: A randomized controlled open-label trial. Eur J Pain 2019; 23 (06) 1162-70
    CrossrefPubMedGoogle Scholar
  • 54 Nielsen M, Carlsen LN, Munksgaard SB. et al Complete withdrawal is the most effective approach to reduce disability in patients with medication-overuse headache: A randomized controlled open-label trial. Cephalalgia 2019; 39 (07) 863-72
    CrossrefPubMedGoogle Scholar
  • 55 Hagen K, Stovner LJ. A randomized controlled trial on medication-overuse headache: outcome after 1 and 4 years. Acta Neurol Scand Suppl 2011; 191: 38-43
    CrossrefPubMedGoogle Scholar
  • 56 Diener HC. Detoxification for medication overuse headache is not necessary. Cephalalgia 2012; 32 (05) 423-7
    CrossrefPubMedGoogle Scholar
  • 57 Tassorelli C, Jensen R, Allena M. et al The added value of an electronic monitoring and alerting system in the management of medication-overuse headache: A controlled multicentre study. Cephalalgia 2017; 37 (12) 1115-25
    CrossrefPubMedGoogle Scholar
  • 58 Jellestad PL, Carlsen LN, Westergaard ML. et al Economic benefits of treating medication-overuse headache – results from the multicenter COMOESTAS project. Cephalalgia 2019; 39 (02) 274-85
    CrossrefPubMedGoogle Scholar
  • 59 Pijpers JA, Kies DA, Louter MA. et al Acute withdrawal and botulinum toxin A in chronic migraine with medication overuse: a double-blind randomized controlled trial. Brain 2019; 142 (05) 1203-14
    CrossrefPubMedGoogle Scholar
  • 60 Diener H.-C, Gaul C, Kropp P. et al Kopfschmerz bei Übergebrauch von Schmerz- oder Migränemitteln (Medication Overuse Headache = MOH), S1-Leitlinie. In: Deutsche Gesellschaft für Neurologie (Hrsg.), Leitlinien für Diagnostik und Therapie in der Neurologie. 2018
    PubMedGoogle Scholar
  • 61 Gaul C, Liesering-Latta E, Schäfer B. et al Integrated multidisciplinary care of headache disorders: A narrative review. Cephalalgia 2016; 36 (12) 1181-91
    CrossrefPubMedGoogle Scholar
  • 62 Chiang CC, Schwedt TJ, Wang SJ. et al Treatment of medication-overuse headache: A systematic review. Cephalalgia 2016; 36 (04) 371-86
    CrossrefPubMedGoogle Scholar
  • 63 Grazzi L, Andrasik F. Medication-overuse headache: description, treatment, and relapse prevention. Curr Pain Headache Rep 2006; 10 (01) 71-7
    CrossrefPubMedGoogle Scholar
  • 64 Katsarava Z, Muessig M, Dzagnidze A. et al Medication overuse headache: rates and predictors for relapse in a 4-year prospective study. Cephalalgia 2005; 25 (01) 12-5
    CrossrefPubMedGoogle Scholar
  • 65 Rossi P, Faroni JV, Nappi G. Medication overuse headache: predictors and rates of relapse in migraine patients with low medical needs. A 1-year prospective study. Cephalalgia 2008; 28 (11) 1196-200
    CrossrefPubMedGoogle Scholar
  • 66 Yuan X, Jiang W, Ren X. et al Predictors of relapse in patients with medication overuse headache in Shanghai: A retrospective study with a 6-month follow-up. J Clin Neurosci 2019; 70: 33-6
    CrossrefPubMedGoogle Scholar